{"gene":"ERBB4","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1993,"finding":"Heregulin (neuregulin) is a specific ligand for HER4/ErbB4 that directly activates HER4's intrinsic tyrosine kinase activity and induces tyrosine phosphorylation; heregulin fails to phosphorylate HER2 in the absence of HER4, indicating HER4 is required for heregulin signal transduction.","method":"Ligand binding assays and receptor phosphorylation studies using recombinant heregulin on cell lines expressing recombinant receptors","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct biochemical assay with recombinant ligand and receptor, replicated across multiple cell lines, foundational paper","pmids":["7902537"],"is_preprint":false},{"year":1995,"finding":"ErbB4 is an essential in vivo receptor for neuregulins in cardiac muscle differentiation (myocardial trabeculation) and axon guidance in the CNS hindbrain; ErbB4-null mice die mid-embryogenesis from failed ventricular trabeculation.","method":"ErbB4 knockout mice (gene targeting), histological and developmental phenotype analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with specific developmental phenotypes, replicated across multiple developmental contexts, foundational in vivo study","pmids":["7477376"],"is_preprint":false},{"year":1995,"finding":"Heregulin-induced HER4 activation leads to tyrosine phosphorylation of Shc adaptor proteins, implicating Shc as a downstream signaling molecule in HER4-mediated signal transduction.","method":"Heregulin-Fc fusion protein stimulation of HER4-expressing cells, immunoprecipitation and anti-phosphotyrosine Western blot of Shc","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical identification of downstream signaling partner, single lab, two orthogonal methods (binding + phosphorylation)","pmids":["7759543"],"is_preprint":false},{"year":1998,"finding":"ErbB4 homodimerization at high expression levels is required for neuregulin-stimulated, IL-3-independent cell proliferation; low ErbB4 expression allows neuregulin-induced phosphorylation but is insufficient to couple activated ErbB4 to mitogenic cellular signaling.","method":"Hammerhead ribozyme-mediated ErbB4 knockdown in 32D/ErbB4 cells, proliferation assays, receptor phosphorylation analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ribozyme KD with quantitative expression and signaling analysis, single lab with multiple readouts","pmids":["9699674"],"is_preprint":false},{"year":2000,"finding":"TACE (tumor necrosis factor-alpha-converting enzyme/ADAM17) is the metalloprotease required for regulated ectodomain shedding of the HER4 JM-a isoform; the juxtamembrane sequence specific to JM-a confers susceptibility to TACE-mediated cleavage, while JM-b is resistant.","method":"TACE-deficient cells with TACE re-expression, phorbol ester and pervanadate stimulation, JM-a/JM-b isoform swap experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic loss-of-function (TACE-null cells) plus re-expression rescue, isoform domain-swap experiments, multiple stimuli tested","pmids":["10744726"],"is_preprint":false},{"year":2000,"finding":"The two cytoplasmic ErbB4 isoforms (CYT-1 and CYT-2) differ in signaling: both couple to the Shc-MAPK pathway, but only CYT-1 activates PI3K-Akt signaling; CYT-2 isoform is defective in stimulating cellular survival and chemotaxis, while both can stimulate proliferation.","method":"Isoform expression in cells, signaling pathway analysis (PI3K, Akt, MAPK), functional assays (survival, chemotaxis, proliferation)","journal":"Trends in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform comparison with multiple functional readouts, single lab, review article summarizing original data","pmids":["11343971"],"is_preprint":false},{"year":2005,"finding":"Presenilin-dependent gamma-secretase processing of ErbB4 is required to release the 4ICD intracellular domain; the gamma-secretase-resistant transmembrane mutant ERBB4-V673I retains normal cell-surface signaling but fails to translocate to the nucleus, cannot activate STAT5A-driven beta-casein promoter, and fails to accumulate in mitochondria or induce apoptosis.","method":"Site-directed mutagenesis (V673I), gamma-secretase inhibitors, nuclear fractionation, STAT5A transcriptional reporter assay, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis, multiple orthogonal functional readouts (nuclear localization, transcription, apoptosis), clear mechanistic dissection","pmids":["15746097"],"is_preprint":false},{"year":2005,"finding":"ERBB4 potentiates STAT5A transcriptional activity through phosphorylation of STAT5A at Ser-127/Ser-128 (required for subsequent Tyr-694 phosphorylation and DNA binding) and Ser-779 (required for stable interaction with ERBB4 and gene activation); ERBB4 expression is required in vivo for STAT5A Ser-779 phosphorylation in mammary gland.","method":"Mass spectrometry identification of phosphorylation sites, serine-to-alanine mutagenesis of STAT5A, co-IP, mammary gland immunohistochemistry from ERBB4-null mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — MS site identification combined with mutagenesis, in vitro plus in vivo validation in ERBB4-null tissue, multiple orthogonal methods","pmids":["15863494"],"is_preprint":false},{"year":2006,"finding":"Ligand-activated ERBB4 undergoes proteolytic processing to release 4ICD, which accumulates in mitochondria and promotes cytochrome c efflux; 4ICD functions as a BH3-only protein requiring an intact BH3 domain and BAK (not BAX) to initiate mitochondrial apoptosis; BCL-2 interaction suppresses 4ICD-induced apoptosis.","method":"Ligand stimulation, subcellular fractionation, BH3 domain mutagenesis, BCL-2 overexpression, BAK/BAX siRNA knockdown, cytochrome c release assay, xenograft model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including mutagenesis, fractionation, genetic knockdown, and in vivo validation in a single study","pmids":["16778220"],"is_preprint":false},{"year":2006,"finding":"Estrogen promotes association between estrogen receptor alpha (ERα) and ERBB4; the proteolytically processed 4ICD translocates to the nucleus in a ligand-bound ER-dependent manner and the nuclear ER/4ICD complex selectively coactivates estrogen-inducible promoters (PgR, SDF-1 but not pS2); ERBB4 is itself an estrogen-inducible gene, establishing an autocrine loop.","method":"Co-immunoprecipitation, nuclear translocation assay, chromatin immunoprecipitation, siRNA knockdown, transcriptional reporter assays, cell proliferation assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reciprocal Co-IP, ChIP, siRNA KD with multiple transcriptional readouts, all in single lab with orthogonal methods","pmids":["16912174"],"is_preprint":false},{"year":2006,"finding":"An activating transmembrane mutation (I658E) in ERBB4 increases receptor tyrosine phosphorylation ~5-fold, enhances nuclear translocation and STAT5A-driven beta-casein promoter activation, and potentiates proapoptotic function in multiple cancer cell lines while untransformed cells are resistant.","method":"Site-directed mutagenesis, tyrosine phosphorylation assay, nuclear fractionation, STAT5A transcriptional reporter, apoptosis assays across multiple cell lines","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis with multiple functional readouts, single lab","pmids":["16832345"],"is_preprint":false},{"year":2006,"finding":"Heregulin/HER4-induced growth inhibition and G2/M delay in breast cancer cells requires BRCA1 induction via JNK signaling; HER4 activates JNK to upregulate BRCA1 expression independent of HER2 and cell cycle phase; BRCA1 knockdown abolishes HER4-mediated mitotic delay.","method":"Heregulin stimulation, pharmacological JNK/ERK inhibition, siRNA BRCA1 knockdown, isogenic BRCA1+/- mouse mammary epithelial cells, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (isogenic BRCA1 +/-), siRNA KD, pharmacological inhibition all converging on same mechanism, single lab with multiple orthogonal approaches","pmids":["16914727"],"is_preprint":false},{"year":2007,"finding":"The CYT-2 ErbB4 ICD (ICD2) accumulates in the nucleus to a significantly greater extent than CYT-1 ICD (ICD1); ICD2 shows higher tyrosine phosphorylation and greater in vitro kinase activity than ICD1; kinase-dead ICD2 K751R mutation blocks tyrosine phosphorylation and significantly reduces nuclear translocation; ICD2 is more efficient than ICD1 in promoting STAT5 target gene beta-casein transcription.","method":"Confocal microscopy, nuclear fractionation, in vitro kinase assay, site-directed mutagenesis (K751R), STAT5 transcriptional reporter","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (imaging, fractionation, in vitro kinase, mutagenesis, transcription), mechanistic dissection of isoform-specific nuclear localization","pmids":["17486069"],"is_preprint":false},{"year":2007,"finding":"ErbB4, as a postsynaptic target of NRG1, is recruited into excitatory synapses by synaptic activity; overexpressed ErbB4 selectively enhances AMPA synaptic currents and increases dendritic spine size; preventing NRG1/ErbB4 signaling destabilizes synaptic AMPA receptors and causes loss of synaptic NMDA currents and spines.","method":"Electrophysiology (patch clamp), ErbB4 overexpression and dominant negative, live imaging, spine morphology analysis in hippocampal neurons","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct electrophysiological measurements combined with structural (spine) readouts, gain- and loss-of-function approaches, multiple orthogonal methods","pmids":["17521571"],"is_preprint":false},{"year":2008,"finding":"Crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms reveal that active ErbB4 kinase adopts an asymmetric dimer conformation identical to that of activated EGFR/ErbB1; mutagenesis of intact ErbB4 in Ba/F3 cells confirms the functional importance of this asymmetric dimer for ErbB4 activation; lapatinib binds an inactive kinase conformation.","method":"X-ray crystallography, site-directed mutagenesis, functional kinase activity assays in Ba/F3 cells","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis validation in cells, multiple orthogonal methods in single rigorous study","pmids":["18334220"],"is_preprint":false},{"year":2008,"finding":"4ICD functions as an ERα coactivator and, upon tamoxifen treatment, the ERα-4ICD interaction is disrupted while 4ICD accumulates in mitochondria as a proapoptotic BH3-only protein; BAK activation (independent of BAX) and BCL-2 inhibition of tamoxifen apoptosis support 4ICD involvement; HER4 with mutated BH3 domain fails to restore tamoxifen sensitivity in xenograft model.","method":"Co-immunoprecipitation, siRNA knockdown, tamoxifen resistance models, BH3 domain mutagenesis, xenograft experiments, apoptosis assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis, multiple cell models, in vivo xenograft with domain-specific mutant, mechanistic dissection across multiple orthogonal methods","pmids":["18676864"],"is_preprint":false},{"year":2009,"finding":"Her4 kinase domain is activated ~40-fold upon nickel-liposome-mediated dimerization in a concentration-dependent, sigmoidal (cooperative) manner consistent with asymmetric dimer activation; Her3 activates Her2/neu but is a poor activator of Her4; mutation of Her3 C-lobe residues (952)ENI(954) to Her4-corresponding sequence enhances Her3-mediated Her4 activation, demonstrating sequence-specific heterodimerization requirements.","method":"Reconstituted in vitro kinase assay with nickel-chelating lipid-liposomes, autophosphorylation assay, site-directed mutagenesis of Her3","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, direct mechanistic demonstration of asymmetric dimer activation and sequence determinants","pmids":["20022944"],"is_preprint":false},{"year":2010,"finding":"ErbB4 JM-a isoform promotes enhanced autophosphorylation and cell survival via release of soluble ICD that associates with transcription factor AP-2 to promote PDGFRA transcription; JM-b isoform cells undergo starvation-induced death; PDGFR-α and AP-2 are required for JM-a survival; cells expressing JM-b are rescued by PDGF-BB, identifying PDGFRA as an ErbB4 isoform-specific target gene.","method":"ErbB4 isoform expression in fibroblasts, PDGFRA expression analysis, AP-2 co-immunoprecipitation, pharmacological PDGFR-α targeting, rescue experiments with PDGF-BB","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform comparison with mechanistic follow-up (Co-IP, pharmacological and genetic inhibition), single lab","pmids":["20943952"],"is_preprint":false},{"year":2010,"finding":"KRAB-associated protein 1 (Kap1) binds to multiple ErbB4 isoforms independently of ErbB4 kinase activity and is not an ErbB4 substrate; Kap1 reduces ERBB4 transcription; ErbB4 upregulation and MDM2 suppression jointly accelerate p21(CIP1) accumulation in response to DNA damage.","method":"Proteomic screen for ErbB4 ICD interactors, Co-IP, transcriptional analysis, DNA damage response assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — proteomic screen plus Co-IP validation, functional follow-up with DNA damage, single lab","pmids":["20858735"],"is_preprint":false},{"year":2010,"finding":"ErbB4 promotes COX-2 expression in colon epithelial cells by increasing COX-2 mRNA stability through a Src- and PI3K-dependent mechanism; ErbB4 transactivates EGFR upon heregulin stimulation via heterodimerization, and COX-2 inhibition reverses ErbB4-mediated cell survival and soft-agar colony formation.","method":"ErbB4 overexpression and siRNA knockdown, mRNA stability assay, pharmacological inhibition of Src/PI3K/COX-2, EGFR phosphorylation assay, anchorage-independent growth assay","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling pathway inhibitors plus siRNA KD with mechanistic readouts, single lab","pmids":["20585313"],"is_preprint":false},{"year":2013,"finding":"ErbB4 associates with GABAA receptor α1 subunit (GABAR α1) in hippocampal interneurons; a NRG1-mediated ErbB4 signaling pathway, independent of its tyrosine kinase activity, reduces postsynaptic GABAA receptor currents on inhibitory interneurons via clathrin-mediated endocytosis and protein kinase C; ErbB4-null mice have diminished cortical GABAR α1 expression.","method":"Unbiased proteomics, electrophysiology, Co-immunoprecipitation, pharmacological inhibition of endocytosis/PKC, immunohistochemistry, ErbB4-null mice","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — proteomic identification, Co-IP, electrophysiology, pharmacological dissection, and genetic KO all converging on same mechanism in single study","pmids":["24218551"],"is_preprint":false},{"year":2013,"finding":"ALS19-associated ERBB4 mutations (p.Arg927Gln in kinase domain; p.Arg1275Trp in C-terminal domain) reduce autophosphorylation of ErbB4 upon NRG-1 stimulation, establishing that loss of neuregulin-ErbB4 signaling underlies ALS pathogenesis.","method":"Functional analysis of ERBB4 mutants: ErbB4 autophosphorylation assay upon NRG-1 stimulation, comparison of wild-type vs. mutant receptor activity","journal":"American Journal of Human Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay of patient-derived mutants, single lab, limited to autophosphorylation readout","pmids":["24119685"],"is_preprint":false},{"year":2015,"finding":"ERBB4 activates the SREBP-2 cholesterol biosynthetic pathway via PI3K and mTORC1/2 (but not AKT or mTORC1 alone) signaling downstream; NRG1-activated ERBB4 ICD induces SREBP-2 target genes (HMGCR, HMGCS1, LDLR) to increase LDL uptake and cholesterol biosynthesis; SREBP site 1 protease inhibition or pan-ERBB inhibition (lapatinib) blocks NRG1-induced cholesterol gene expression.","method":"ERBB4 ICD expression in mammary epithelial cells, NRG1 stimulation, pharmacological inhibitors of PI3K/mTOR/AKT/lapatinib/erlotinib, gene expression analysis, LDL uptake assay","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors and gene expression validation, single lab","pmids":["26535009"],"is_preprint":false},{"year":2015,"finding":"Four activating ERBB4 mutations in lung adenocarcinoma (Y285C, D595V, D931Y, K935I) increase basal and ligand-induced ErbB4 phosphorylation, enhance ErbB4 dimerization and trans-activation in both homodimers and ErbB4-ErbB2 heterodimers, and markedly increase proteolytic release of signaling-competent ErbB4 ICD.","method":"Mutant ERBB4 expression in NIH 3T3 cells, phosphorylation assays, dimerization assays, structural analysis, ICD release measurement","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional characterization of multiple mutants with mechanistic assays (dimerization, phosphorylation, ICD release), single lab","pmids":["26050618"],"is_preprint":false},{"year":2017,"finding":"ErbB4 in pro-inflammatory macrophages localizes to mitochondria; NRG4-induced ErbB4 activation causes mitochondrial membrane potential loss and apoptosis requiring proteases that generate the cleaved ErbB4 ICD, consistent with mitochondrial pathway apoptosis; NRG4/ErbB4 signaling limits colitis by clearing pro-inflammatory macrophages.","method":"Immunofluorescence (ErbB4 mitochondrial localization), NRG4 treatment, pharmacological protease inhibition, mitochondrial membrane potential assay, apoptosis assays in murine and human macrophages, DSS colitis model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment tied to functional consequence, pharmacological dissection, in vivo colitis model, single lab","pmids":["28230865"],"is_preprint":false},{"year":2017,"finding":"ErbB4 deletion in the liver suppresses p53 expression by inhibiting TP53INP1 expression, establishing an ERBB4-TP53INP1-P53 axis in hepatocellular carcinoma suppression.","method":"Liver-specific ErbB4 knockout mice, DEN-induced tumor model, microarray gene expression analysis, real-time PCR validation","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with mechanistic pathway identification via transcriptomics plus validation, single lab","pmids":["28334319"],"is_preprint":false},{"year":2018,"finding":"ErbB4 promotes inhibitory synapse formation through kinase-independent trans-adhesion: ErbB4 interacts in trans with postsynaptic Slitrk3 via ErbB4's extracellular RLD domain; kinase-dead ErbB4 K751M knock-in mice have normal inhibitory synapse numbers (unlike ErbB4-null mice), confirming kinase-independent mechanism.","method":"HEK293T co-culture synapse formation assay, K751M kinase-dead mutant KI mice, ErbB4 RLD domain deletion, Slitrk3 neutralization, GABAergic transmission electrophysiology, immunostaining","journal":"Translational psychiatry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis (kinase dead), KI mice, domain deletion, neutralization experiments, electrophysiology—multiple orthogonal methods establishing kinase-independent adhesion mechanism","pmids":["34226493"],"is_preprint":false},{"year":2018,"finding":"S100A4 neuroprotection depends on ErbB4 expression and ErbB2/Akt signaling downstream of ErbB4; S100A4 and S100A4-derived peptides interact with ErbB4 (as well as ErbB1 and ErbB3) and signal through ErbB receptors to promote neuronal survival.","method":"ErbB4 expression-dependent neuroprotection assays, functional ErbB4 blockade, ErbB2/Akt inhibition, binding assays","journal":"Theranostics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, binding and functional assays without full mechanistic resolution of direct vs. indirect S100A4-ErbB4 interaction","pmids":["30083275"],"is_preprint":false},{"year":2018,"finding":"Acute ErbB4 kinase inactivation (chemical genetics) and optogenetic inhibition of ErbB4+ interneurons in the hippocampus reduce GABAergic activity, impair hippocampal-prefrontal synchrony, and diminish top-down attention; ErbB4 inactivation in prefrontal cortex alters attention but not synchrony, establishing hippocampal ErbB4 as specifically required for hippocampal-prefrontal synchronization.","method":"Chemical genetic ErbB4 kinase inactivation, optogenetic interneuron inhibition, in vivo LFP recording, attention behavioral assays in ErbB4 mutant mice","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — chemical genetics plus optogenetics with in vivo electrophysiology, region-specific dissection, multiple complementary approaches","pmids":["29628188"],"is_preprint":false},{"year":2011,"finding":"TNF transactivates ErbB4 through TACE-dependent release of HB-EGF; MEK (but not Src or p38) is required for this transactivation; TACE inhibition or ErbB4 ligand-binding blockade reverses ErbB4-mediated protection of colonic epithelial cells from TNF-induced apoptosis.","method":"Neutralizing antibodies against HB-EGF, pharmacological/genetic TACE inhibition, MEK/Src/p38 inhibitors, apoptosis assays in ErbB4-expressing mouse colon epithelial cells","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological and antibody-based pathway dissection approaches, single lab","pmids":["21617117"],"is_preprint":false},{"year":2012,"finding":"In adult rat ventricular myocytes (ARVM), ErbB4 localizes to the nucleus as a full-length protein (not requiring PKC or gamma-secretase), as only the non-cleavable JM-b isoform is expressed in ARVM; ErbB4 kinase activity is required for doxorubicin-induced p53 and p21 upregulation in cardiac myocytes.","method":"Nuclear fractionation, isoform expression analysis, gamma-secretase/PKC inhibitors, ErbB4 siRNA knockdown, doxorubicin DNA damage assay, p53/p21 expression analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct fractionation with isoform analysis, pharmacological and siRNA-based functional dissection, single lab","pmids":["22244893"],"is_preprint":false},{"year":2015,"finding":"PTPN21 de-phosphorylates ErbB4, leading to upregulation of ErbB4 downstream signaling; phosphatase-dead PTPN21 (C1108S) and kinase-dead ErbB4 (K751R) both impede PTPN21-dependent signaling; PTPN21 promotes NRG3 expression through Elk-1 activation downstream of ErbB4.","method":"Biotinylated receptor tracking, immunoprecipitation, PTPN21 and ErbB4 kinase-dead mutants, Elk-1 transcriptional analysis, NRG3 promoter analysis in cortical neurons","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP, domain mutants, transcriptional analysis, single lab with multiple approaches","pmids":["25681686"],"is_preprint":false},{"year":2019,"finding":"ErbB4 promotes malignant peripheral nerve sheath tumor (MPNST) proliferation and survival via Ras-independent signaling through STAT3, STAT5, and phospholipase-Cγ pathways; ErbB4 ablation reduces Ras-independent kinase cascades while broad-spectrum ErbB inhibitors suppress Ras activation, demonstrating distinct ErbB4-specific signaling.","method":"Conditional Erbb4 knockout in MPNST mice, orthotopic xenografts of Erbb4-null cells, antibody kinase arrays (43 candidate kinases), pharmacological inhibition of STAT3/STAT5/PLCγ, proliferation and survival assays","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO in vivo plus in vitro kinase array with pharmacological validation, single lab","pmids":["31291965"],"is_preprint":false},{"year":2021,"finding":"ErbB4 mediates Aβ-induced neurotoxicity through JNK/tau pathway activation; Aβ activates JNK via ErbB4 (distinct from NRG1β1-ErbB4 signaling), and ErbB4 siRNA knockdown decreases JNK and tau phosphorylation at Ser396/Thr205, Bax expression, and PSD-95/synaptophysin loss.","method":"ErbB4 siRNA knockdown, ErbB4 kinase inhibitor (AG1478), PV neuron-specific ErbB4 conditional KO, phosphorylation assays for JNK and tau, Western blot, hAPP-J20 mouse model","journal":"The Journal of comparative neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, pharmacological inhibition, and siRNA with mechanistic pathway markers, single lab","pmids":["34212389"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of near full-length HER2/HER4 heterodimers and full-length HER4 homodimers bound to NRG1β and BTC reveal: HER2/HER4 heterodimer interface is less dynamic than HER2/EGFR or HER2/HER3; HER4 homodimers exhibit more large-scale dynamics than HER2/HER4 heterodimers; multiple glycan modifications on HER4 ectodomains stabilize HER4 homodimer interfaces over HER2/HER4 heterodimer interfaces.","method":"Cryo-EM structure determination of near full-length receptor complexes, structural dynamics analysis, glycan modeling","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures with near full-length constructs, multiple complexes compared, first glycan modeling in HER receptors","pmids":["38498590"],"is_preprint":false},{"year":2025,"finding":"Small-molecule compounds (EF-1 to EF-8) can activate ERBB4 by inducing receptor dimerization; EF-1 reduces cardiomyocyte death and hypertrophy and decreases cardiac fibroblast collagen production in an ERBB4-dependent manner; in vivo, EF-1 inhibits angiotensin-II-induced fibrosis and reduces doxorubicin/MI-induced heart damage, with no effect in Erbb4-null mice.","method":"Small-molecule screen (10,240 compounds), ERBB4 dimerization assay, cardiomyocyte and fibroblast cell assays, Erbb4-null mouse model with angiotensin-II, doxorubicin, and MI models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanism validated in Erbb4-null mice (genetic negative control), multiple in vivo cardiac injury models, orthogonal cellular assays","pmids":["39794341"],"is_preprint":false},{"year":2023,"finding":"Peripheral Nrg4 signals via ErbB4 in hypothalamic paraventricular nucleus (PVN) oxytocin neurons; ErbB4 overexpression in PVN protects against obesity while ErbB4 knockdown in oxytocin neurons accelerates obesity; Nrg4-ErbB4 signaling excites oxytocin release, and oxytocin neuron ablation attenuates Nrg4's effect on energy balance.","method":"PVN ErbB4 overexpression, oxytocin neuron-specific ErbB4 knockdown, central rNrg4 administration, oxytocin neuron ablation, metabolic phenotyping in DIO mice","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic manipulations with functional metabolic readouts and epistasis, single lab","pmids":["37060105"],"is_preprint":false}],"current_model":"ERBB4/HER4 is a receptor tyrosine kinase activated by neuregulins (and other EGF-family ligands) that signals through ligand-induced asymmetric kinase domain dimerization, leading to autophosphorylation and downstream activation of Shc-MAPK, PI3K-Akt (isoform-dependent), STAT5A, and PLCγ pathways; uniquely among ErbB receptors, ERBB4 undergoes sequential ectodomain shedding by TACE (isoform JM-a only) followed by presenilin/γ-secretase cleavage to release a soluble intracellular domain (4ICD) that translocates to the nucleus to coactivate STAT5A and ERα-driven transcription, or to mitochondria where it acts as a BH3-only protein to trigger BAK-dependent apoptosis; additionally, ErbB4 promotes inhibitory synapse formation through kinase-independent trans-interaction with Slitrk3 via its extracellular RLD domain, and regulates GABAergic interneuron function to control hippocampal-prefrontal synchrony and cortical circuit activity."},"narrative":{"mechanistic_narrative":"ERBB4/HER4 is a neuregulin-activated receptor tyrosine kinase that couples extracellular EGF-family ligand binding to both canonical cytoplasmic signaling and a distinctive nuclear/mitochondrial signaling mode, with essential roles in cardiac and neural development, GABAergic circuit function, and tissue homeostasis [PMID:7902537, PMID:7477376]. Ligand binding drives formation of an asymmetric kinase-domain dimer structurally identical to that of activated EGFR, which is required for kinase activation and autophosphorylation [PMID:18334220, PMID:20022944], and cryo-EM of near-full-length HER4 homodimers and HER2/HER4 heterodimers shows that glycan modifications and interface dynamics distinguish these dimer states [PMID:38498590]. Activated ERBB4 engages the Shc-MAPK pathway and, in an isoform-dependent manner, PI3K-Akt: the CYT-1 cytoplasmic isoform activates PI3K-Akt and supports survival and chemotaxis whereas CYT-2 does not [PMID:7759543, PMID:11343971]. Uniquely among ErbB receptors, the JM-a isoform undergoes sequential TACE/ADAM17-mediated ectodomain shedding followed by presenilin/γ-secretase cleavage to release a soluble intracellular domain (4ICD); blocking γ-secretase cleavage abolishes nuclear translocation, STAT5A-driven transcription, mitochondrial accumulation, and apoptosis [PMID:10744726, PMID:15746097]. In the nucleus 4ICD potentiates STAT5A activity through direct serine phosphorylation events and coactivates ERα at estrogen-responsive promoters, forming an autocrine loop with estrogen-induced ERBB4 [PMID:15863494, PMID:16912174], while at mitochondria 4ICD acts as a BH3-only protein requiring an intact BH3 domain and BAK to trigger cytochrome c release and apoptosis, an activity suppressed by BCL-2 [PMID:15746097, PMID:18676864]. In the nervous system ErbB4 mediates NRG1 signaling to control excitatory and inhibitory synapses and GABAergic interneuron function, governing hippocampal-prefrontal synchrony and attention [PMID:17521571, PMID:29628188]; it also promotes inhibitory synapse formation through a kinase-independent trans-adhesive interaction with Slitrk3 via its extracellular RLD domain [PMID:34226493]. Timeline evidence links ERBB4 mutations that reduce NRG1-stimulated autophosphorylation to amyotrophic lateral sclerosis (ALS19) [PMID:24119685].","teleology":[{"year":1993,"claim":"Established that HER4/ErbB4 is a functional receptor whose intrinsic kinase is directly activated by heregulin/neuregulin, defining the ligand-receptor relationship at the heart of the pathway.","evidence":"Recombinant heregulin binding and receptor phosphorylation assays in cell lines expressing recombinant receptors","pmids":["7902537"],"confidence":"High","gaps":["Did not resolve downstream effectors","Did not address receptor dimerization or activation mechanism"]},{"year":1995,"claim":"Demonstrated that ErbB4 is an essential in vivo neuregulin receptor, anchoring its developmental requirement in cardiac trabeculation and CNS axon guidance.","evidence":"ErbB4 knockout mice with histological developmental phenotyping","pmids":["7477376"],"confidence":"High","gaps":["Embryonic lethality limits analysis of later/adult roles","Cell-autonomous vs. systemic contributions not separated"]},{"year":1995,"claim":"Identified Shc as an immediate downstream adaptor, beginning the mapping of ErbB4's cytoplasmic signaling outputs.","evidence":"Heregulin-Fc stimulation with Shc immunoprecipitation and anti-phosphotyrosine blotting","pmids":["7759543"],"confidence":"Medium","gaps":["Did not connect Shc to a specific phenotype","Single readout of phosphorylation"]},{"year":2000,"claim":"Resolved the protease and isoform determinants of ectodomain shedding, showing TACE/ADAM17 cleaves only the JM-a isoform — the prerequisite for regulated intracellular signaling.","evidence":"TACE-null cells with re-expression rescue and JM-a/JM-b isoform-swap experiments","pmids":["10744726"],"confidence":"High","gaps":["Did not address the second (gamma-secretase) cleavage step","Physiological triggers of shedding beyond phorbol ester/pervanadate not defined"]},{"year":2000,"claim":"Defined functional divergence of the cytoplasmic CYT-1/CYT-2 isoforms, establishing PI3K-Akt coupling as a CYT-1-specific output for survival and chemotaxis.","evidence":"Isoform expression with PI3K/Akt/MAPK signaling and functional survival, chemotaxis, proliferation assays","pmids":["11343971"],"confidence":"Medium","gaps":["Review-summarized original data","Molecular basis of differential PI3K recruitment not mapped"]},{"year":2005,"claim":"Showed presenilin/gamma-secretase cleavage is required to liberate 4ICD, linking proteolysis to nuclear translocation, STAT5A transcription, and mitochondrial apoptosis through a single non-cleavable mutant.","evidence":"V673I cleavage-resistant mutant, gamma-secretase inhibitors, nuclear fractionation, STAT5A reporter and apoptosis assays","pmids":["15746097"],"confidence":"High","gaps":["Did not define nuclear import machinery","Mitochondrial targeting determinants left open"]},{"year":2005,"claim":"Defined the molecular basis of ERBB4-STAT5A coactivation via specific serine phosphorylations required for STAT5A activation and stable interaction, validated in ERBB4-null mammary tissue.","evidence":"Mass spectrometry site mapping, STAT5A serine-to-alanine mutagenesis, co-IP, and ERBB4-null mammary immunohistochemistry","pmids":["15863494"],"confidence":"High","gaps":["Whether full-length receptor or 4ICD performs the phosphorylation in vivo not fully resolved","Genome-wide STAT5A target scope not defined"]},{"year":2006,"claim":"Established 4ICD as a BH3-only proapoptotic effector, identifying BAK (not BAX) dependence and BCL-2 antagonism as the mitochondrial death mechanism.","evidence":"Subcellular fractionation, BH3 mutagenesis, BAK/BAX siRNA, cytochrome c release, BCL-2 overexpression, and xenografts","pmids":["16778220"],"confidence":"High","gaps":["Direct 4ICD-BAK binding stoichiometry not determined","Conditions favoring apoptotic vs. transcriptional 4ICD fate unclear"]},{"year":2006,"claim":"Linked 4ICD to estrogen signaling as an ERalpha coactivator at selected promoters, with ERBB4 itself estrogen-inducible, establishing an autocrine transcriptional loop.","evidence":"Reciprocal co-IP, ChIP, siRNA knockdown, and transcriptional reporter assays","pmids":["16912174"],"confidence":"High","gaps":["Basis of promoter selectivity (PgR/SDF-1 vs pS2) not explained","Interplay with STAT5A coactivation not addressed"]},{"year":2006,"claim":"Connected ErbB4 to a tumor-suppressive cell-cycle arrest via JNK-driven BRCA1 induction, showing growth-inhibitory as well as proliferative outputs.","evidence":"Heregulin stimulation, JNK/ERK inhibition, BRCA1 siRNA, isogenic BRCA1+/- cells, and cell cycle analysis","pmids":["16914727"],"confidence":"High","gaps":["How JNK is selectively engaged by ErbB4 not defined","Reconciliation with proliferative signaling context-dependent"]},{"year":2008,"claim":"Provided the structural basis of ErbB4 kinase activation, showing the active kinase forms an asymmetric dimer identical to EGFR and that lapatinib traps an inactive conformation.","evidence":"X-ray crystallography of active and lapatinib-bound kinase domains plus mutagenesis in Ba/F3 cells","pmids":["18334220"],"confidence":"High","gaps":["Full-length ectodomain-mediated dimerization not captured","Heterodimer-specific activation not addressed structurally"]},{"year":2009,"claim":"Quantified cooperative asymmetric-dimer activation in vitro and defined C-lobe sequence determinants governing which partner activates Her4, explaining heterodimer selectivity.","evidence":"Reconstituted nickel-liposome kinase assays with Her3 C-lobe mutagenesis","pmids":["20022944"],"confidence":"High","gaps":["In vitro liposome system may not capture full-length cellular regulation","Physiological partner hierarchy in cells not ranked"]},{"year":null,"claim":"Multiple isoform-, mutation-, and context-specific signaling outputs (CYT-1/CYT-2 nuclear potency, PDGFRA/AP-2 and SREBP-2 transcriptional programs, KAP1/PTPN21 regulation, cancer-activating mutations, neuronal NRG/ErbB4 circuit and disease links in ALS and Alzheimer's, and cardioprotective small-molecule agonism) extend the model but the rules that select between cytoplasmic, nuclear-transcriptional, and mitochondrial-apoptotic ErbB4 fates in a given cell remain unresolved.","evidence":"Spanning isoform, proteomic, mutational, metabolic, neuronal, and pharmacological studies across the timeline","pmids":[],"confidence":"Medium","gaps":["No unifying determinant of 4ICD trafficking fate","Direct S100A4-ErbB4 interaction not resolved (Low-confidence)","Disease mechanisms beyond receptor-level readouts incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,7,14,16]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,13]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[7,9,17]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[26]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[6,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,14]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,9,12,30]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[6,15,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,5,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,15,24]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,9,17]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[13,20,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1]}],"complexes":[],"partners":["NRG1","SHC1","STAT5A","ESR1","BAK1","BCL2","SLITRK3","PTPN21"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15303","full_name":"Receptor tyrosine-protein kinase erbB-4","aliases":["Proto-oncogene-like protein c-ErbB-4","Tyrosine kinase-type cell surface receptor HER4","p180erbB4"],"length_aa":1308,"mass_kda":146.8,"function":"Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis","subcellular_location":"Nucleus; Mitochondrion","url":"https://www.uniprot.org/uniprotkb/Q15303/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERBB4","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERBB4","total_profiled":1310},"omim":[{"mim_id":"620051","title":"RING FINGER PROTEIN 41, E3 UBIQUITIN PROTEIN LIGASE; RNF41","url":"https://www.omim.org/entry/620051"},{"mim_id":"618717","title":"EPITHELIAL MITOGEN; EPGN","url":"https://www.omim.org/entry/618717"},{"mim_id":"615515","title":"AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19","url":"https://www.omim.org/entry/615515"},{"mim_id":"613746","title":"BREAST CANCER ANTIESTROGEN RESISTANCE 4; BCAR4","url":"https://www.omim.org/entry/613746"},{"mim_id":"612082","title":"CAPICUA TRANSCRIPTIONAL REPRESSOR; CIC","url":"https://www.omim.org/entry/612082"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":7.6},{"tissue":"brain","ntpm":7.7},{"tissue":"fallopian tube","ntpm":10.6}],"url":"https://www.proteinatlas.org/search/ERBB4"},"hgnc":{"alias_symbol":["ALS19","HER4"],"prev_symbol":[]},"alphafold":{"accession":"Q15303","domains":[{"cath_id":"3.80.20.20","chopping":"29-209","consensus_level":"high","plddt":90.9034,"start":29,"end":209},{"cath_id":"2.10.220.10","chopping":"262-326","consensus_level":"medium","plddt":84.0962,"start":262,"end":326},{"cath_id":"3.80.20.20","chopping":"341-502","consensus_level":"medium","plddt":93.5826,"start":341,"end":502},{"cath_id":"2.10.220.10","chopping":"593-637","consensus_level":"medium","plddt":86.6856,"start":593,"end":637},{"cath_id":"3.30.200.20","chopping":"710-799","consensus_level":"medium","plddt":79.1919,"start":710,"end":799},{"cath_id":"1.10.510.10","chopping":"803-869_878-1008","consensus_level":"medium","plddt":87.4057,"start":803,"end":1008}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15303","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15303-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15303-F1-predicted_aligned_error_v6.png","plddt_mean":73.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERBB4","jax_strain_url":"https://www.jax.org/strain/search?query=ERBB4"},"sequence":{"accession":"Q15303","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15303.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15303/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15303"}},"corpus_meta":[{"pmid":"7477376","id":"PMC_7477376","title":"Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7477376","citation_count":930,"is_preprint":false},{"pmid":"7902537","id":"PMC_7902537","title":"Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7902537","citation_count":471,"is_preprint":false},{"pmid":"17521571","id":"PMC_17521571","title":"The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity.","date":"2007","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17521571","citation_count":291,"is_preprint":false},{"pmid":"10744726","id":"PMC_10744726","title":"Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10744726","citation_count":265,"is_preprint":false},{"pmid":"15543145","id":"PMC_15543145","title":"Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain.","date":"2004","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15543145","citation_count":205,"is_preprint":false},{"pmid":"12648466","id":"PMC_12648466","title":"ErbB-4: mechanism of action and biology.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648466","citation_count":194,"is_preprint":false},{"pmid":"16778220","id":"PMC_16778220","title":"The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16778220","citation_count":173,"is_preprint":false},{"pmid":"18243664","id":"PMC_18243664","title":"Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients.","date":"2008","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18243664","citation_count":150,"is_preprint":false},{"pmid":"18334220","id":"PMC_18334220","title":"Mechanism of activation and inhibition of the HER4/ErbB4 kinase.","date":"2008","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/18334220","citation_count":141,"is_preprint":false},{"pmid":"24119685","id":"PMC_24119685","title":"ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24119685","citation_count":124,"is_preprint":false},{"pmid":"16912174","id":"PMC_16912174","title":"Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16912174","citation_count":123,"is_preprint":false},{"pmid":"15788662","id":"PMC_15788662","title":"Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15788662","citation_count":122,"is_preprint":false},{"pmid":"18454307","id":"PMC_18454307","title":"Role of ErbB4 in breast cancer.","date":"2008","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/18454307","citation_count":117,"is_preprint":false},{"pmid":"11343971","id":"PMC_11343971","title":"Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants.","date":"2000","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11343971","citation_count":115,"is_preprint":false},{"pmid":"15746097","id":"PMC_15746097","title":"Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15746097","citation_count":110,"is_preprint":false},{"pmid":"21811097","id":"PMC_21811097","title":"Function of ERBB4 is determined by alternative splicing.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21811097","citation_count":98,"is_preprint":false},{"pmid":"15944951","id":"PMC_15944951","title":"The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.","date":"2005","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/15944951","citation_count":97,"is_preprint":false},{"pmid":"32219702","id":"PMC_32219702","title":"The role of ErbB4 in cancer.","date":"2020","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/32219702","citation_count":89,"is_preprint":false},{"pmid":"18437540","id":"PMC_18437540","title":"ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.","date":"2008","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/18437540","citation_count":83,"is_preprint":false},{"pmid":"28230865","id":"PMC_28230865","title":"ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28230865","citation_count":81,"is_preprint":false},{"pmid":"25916654","id":"PMC_25916654","title":"ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.","date":"2015","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25916654","citation_count":78,"is_preprint":false},{"pmid":"15583696","id":"PMC_15583696","title":"Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15583696","citation_count":72,"is_preprint":false},{"pmid":"16685269","id":"PMC_16685269","title":"The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16685269","citation_count":72,"is_preprint":false},{"pmid":"18473151","id":"PMC_18473151","title":"HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.","date":"2008","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/18473151","citation_count":71,"is_preprint":false},{"pmid":"33219358","id":"PMC_33219358","title":"miR-323a regulates ERBB4 and is involved in depression.","date":"2020","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33219358","citation_count":66,"is_preprint":false},{"pmid":"25590338","id":"PMC_25590338","title":"Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.","date":"2015","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25590338","citation_count":66,"is_preprint":false},{"pmid":"19481955","id":"PMC_19481955","title":"The upgraded role of HER3 and HER4 receptors in breast cancer.","date":"2009","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19481955","citation_count":65,"is_preprint":false},{"pmid":"29628188","id":"PMC_29628188","title":"Dynamic ErbB4 Activity in Hippocampal-Prefrontal Synchrony and Top-Down Attention in Rodents.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29628188","citation_count":65,"is_preprint":false},{"pmid":"26050618","id":"PMC_26050618","title":"Activating ERBB4 mutations in non-small cell lung cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26050618","citation_count":63,"is_preprint":false},{"pmid":"34987087","id":"PMC_34987087","title":"The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.","date":"2022","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34987087","citation_count":60,"is_preprint":false},{"pmid":"34885957","id":"PMC_34885957","title":"A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34885957","citation_count":57,"is_preprint":false},{"pmid":"17486069","id":"PMC_17486069","title":"Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17486069","citation_count":55,"is_preprint":false},{"pmid":"20022944","id":"PMC_20022944","title":"Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20022944","citation_count":54,"is_preprint":false},{"pmid":"18676864","id":"PMC_18676864","title":"The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18676864","citation_count":54,"is_preprint":false},{"pmid":"20943952","id":"PMC_20943952","title":"Cell death or survival promoted by alternative isoforms of ErbB4.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20943952","citation_count":52,"is_preprint":false},{"pmid":"29179520","id":"PMC_29179520","title":"A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29179520","citation_count":51,"is_preprint":false},{"pmid":"12845622","id":"PMC_12845622","title":"c-erbB-4/HER4: friend or foe?","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12845622","citation_count":51,"is_preprint":false},{"pmid":"30120408","id":"PMC_30120408","title":"Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders.","date":"2018","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30120408","citation_count":46,"is_preprint":false},{"pmid":"24901400","id":"PMC_24901400","title":"High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.","date":"2014","source":"International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists","url":"https://pubmed.ncbi.nlm.nih.gov/24901400","citation_count":45,"is_preprint":false},{"pmid":"12813928","id":"PMC_12813928","title":"The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4.","date":"2003","source":"Transactions of the American Clinical and Climatological Association","url":"https://pubmed.ncbi.nlm.nih.gov/12813928","citation_count":44,"is_preprint":false},{"pmid":"16832345","id":"PMC_16832345","title":"A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16832345","citation_count":43,"is_preprint":false},{"pmid":"22076439","id":"PMC_22076439","title":"ErbB4 modulates tubular cell polarity and lumen diameter during kidney development.","date":"2011","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22076439","citation_count":42,"is_preprint":false},{"pmid":"15863494","id":"PMC_15863494","title":"ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15863494","citation_count":41,"is_preprint":false},{"pmid":"30083275","id":"PMC_30083275","title":"The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/30083275","citation_count":40,"is_preprint":false},{"pmid":"21769435","id":"PMC_21769435","title":"Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.","date":"2011","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21769435","citation_count":40,"is_preprint":false},{"pmid":"20603612","id":"PMC_20603612","title":"Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20603612","citation_count":39,"is_preprint":false},{"pmid":"16914727","id":"PMC_16914727","title":"Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16914727","citation_count":37,"is_preprint":false},{"pmid":"28573357","id":"PMC_28573357","title":"Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.","date":"2017","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/28573357","citation_count":36,"is_preprint":false},{"pmid":"29398709","id":"PMC_29398709","title":"Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29398709","citation_count":35,"is_preprint":false},{"pmid":"26535009","id":"PMC_26535009","title":"Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake.","date":"2015","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26535009","citation_count":35,"is_preprint":false},{"pmid":"32618511","id":"PMC_32618511","title":"The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling.","date":"2020","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32618511","citation_count":33,"is_preprint":false},{"pmid":"28675393","id":"PMC_28675393","title":"ErbB4 signaling in the prelimbic cortex regulates fear expression.","date":"2017","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/28675393","citation_count":32,"is_preprint":false},{"pmid":"33826403","id":"PMC_33826403","title":"NRG4-ErbB4 signaling represses proinflammatory macrophage activity.","date":"2021","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33826403","citation_count":31,"is_preprint":false},{"pmid":"24728052","id":"PMC_24728052","title":"Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24728052","citation_count":31,"is_preprint":false},{"pmid":"21513767","id":"PMC_21513767","title":"Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21513767","citation_count":30,"is_preprint":false},{"pmid":"24218551","id":"PMC_24218551","title":"ErbB4 reduces synaptic GABAA currents independent of its receptor tyrosine kinase activity.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24218551","citation_count":30,"is_preprint":false},{"pmid":"7535774","id":"PMC_7535774","title":"HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7535774","citation_count":29,"is_preprint":false},{"pmid":"28273943","id":"PMC_28273943","title":"Increased NRG1-ErbB4 signaling in human symptomatic epilepsy.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28273943","citation_count":28,"is_preprint":false},{"pmid":"16606438","id":"PMC_16606438","title":"HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.","date":"2006","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/16606438","citation_count":28,"is_preprint":false},{"pmid":"28334319","id":"PMC_28334319","title":"ERBB4 acts as a suppressor in the development of hepatocellular carcinoma.","date":"2017","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28334319","citation_count":28,"is_preprint":false},{"pmid":"9581810","id":"PMC_9581810","title":"Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9581810","citation_count":28,"is_preprint":false},{"pmid":"28724608","id":"PMC_28724608","title":"ErbB4 deletion accelerates renal fibrosis following renal injury.","date":"2017","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28724608","citation_count":27,"is_preprint":false},{"pmid":"34212389","id":"PMC_34212389","title":"ErbB4 mediates amyloid β-induced neurotoxicity through JNK/tau pathway activation: Implications for Alzheimer's disease.","date":"2021","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34212389","citation_count":27,"is_preprint":false},{"pmid":"7759543","id":"PMC_7759543","title":"HER4 receptor activation and phosphorylation of Shc proteins by recombinant heregulin-Fc fusion proteins.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7759543","citation_count":27,"is_preprint":false},{"pmid":"14504474","id":"PMC_14504474","title":"ErbB4 signaling during breast and neural development: novel genetic models reveal unique ErbB4 activities.","date":"2003","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/14504474","citation_count":26,"is_preprint":false},{"pmid":"20550710","id":"PMC_20550710","title":"The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20550710","citation_count":26,"is_preprint":false},{"pmid":"14672400","id":"PMC_14672400","title":"Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).","date":"2003","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/14672400","citation_count":26,"is_preprint":false},{"pmid":"24091566","id":"PMC_24091566","title":"HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.","date":"2013","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24091566","citation_count":26,"is_preprint":false},{"pmid":"37060105","id":"PMC_37060105","title":"Neuregulin4 Acts on Hypothalamic ErBb4 to Excite Oxytocin Neurons and Preserve Metabolic Homeostasis.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37060105","citation_count":25,"is_preprint":false},{"pmid":"7700649","id":"PMC_7700649","title":"Localization of the human HER4/erbB-4 gene to chromosome 2.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7700649","citation_count":25,"is_preprint":false},{"pmid":"23316969","id":"PMC_23316969","title":"Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.","date":"2013","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/23316969","citation_count":25,"is_preprint":false},{"pmid":"21617117","id":"PMC_21617117","title":"TNF-α converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival.","date":"2011","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21617117","citation_count":25,"is_preprint":false},{"pmid":"32716031","id":"PMC_32716031","title":"Erbb4 regulates the oocyte microenvironment during folliculogenesis.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32716031","citation_count":24,"is_preprint":false},{"pmid":"20585313","id":"PMC_20585313","title":"ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.","date":"2010","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20585313","citation_count":24,"is_preprint":false},{"pmid":"20858735","id":"PMC_20858735","title":"Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/20858735","citation_count":24,"is_preprint":false},{"pmid":"24258993","id":"PMC_24258993","title":"ERBB4 mutation analysis: emerging molecular target for melanoma treatment.","date":"2014","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/24258993","citation_count":24,"is_preprint":false},{"pmid":"22087295","id":"PMC_22087295","title":"Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta).","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22087295","citation_count":24,"is_preprint":false},{"pmid":"24829397","id":"PMC_24829397","title":"Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24829397","citation_count":24,"is_preprint":false},{"pmid":"29524631","id":"PMC_29524631","title":"HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29524631","citation_count":22,"is_preprint":false},{"pmid":"32065797","id":"PMC_32065797","title":"ErbB4 Mutation that Decreased NRG1-ErbB4 Signaling Involved in the Pathogenesis of Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.","date":"2020","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/32065797","citation_count":22,"is_preprint":false},{"pmid":"34226493","id":"PMC_34226493","title":"ErbB4 promotes inhibitory synapse formation by cell adhesion, independent of its kinase activity.","date":"2021","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34226493","citation_count":21,"is_preprint":false},{"pmid":"31291965","id":"PMC_31291965","title":"ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.","date":"2019","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/31291965","citation_count":21,"is_preprint":false},{"pmid":"25681686","id":"PMC_25681686","title":"PTPN21 exerts pro-neuronal survival and neuritic elongation via ErbB4/NRG3 signaling.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25681686","citation_count":20,"is_preprint":false},{"pmid":"29410073","id":"PMC_29410073","title":"The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation.","date":"2018","source":"Biochimica et biophysica acta. General subjects","url":"https://pubmed.ncbi.nlm.nih.gov/29410073","citation_count":19,"is_preprint":false},{"pmid":"20087905","id":"PMC_20087905","title":"Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.","date":"2010","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20087905","citation_count":19,"is_preprint":false},{"pmid":"10383375","id":"PMC_10383375","title":"Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10383375","citation_count":19,"is_preprint":false},{"pmid":"9699674","id":"PMC_9699674","title":"ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9699674","citation_count":19,"is_preprint":false},{"pmid":"25492964","id":"PMC_25492964","title":"Neuregulin 1-activated ERBB4 as a \"dedicated\" receptor for the Hippo-YAP pathway.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25492964","citation_count":18,"is_preprint":false},{"pmid":"34237622","id":"PMC_34237622","title":"Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34237622","citation_count":18,"is_preprint":false},{"pmid":"32201081","id":"PMC_32201081","title":"Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32201081","citation_count":18,"is_preprint":false},{"pmid":"32181480","id":"PMC_32181480","title":"HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.","date":"2020","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/32181480","citation_count":17,"is_preprint":false},{"pmid":"34247489","id":"PMC_34247489","title":"ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy.","date":"2021","source":"Circulation. Heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/34247489","citation_count":17,"is_preprint":false},{"pmid":"22244893","id":"PMC_22244893","title":"ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22244893","citation_count":17,"is_preprint":false},{"pmid":"38498590","id":"PMC_38498590","title":"Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/38498590","citation_count":16,"is_preprint":false},{"pmid":"38589689","id":"PMC_38589689","title":"Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38589689","citation_count":15,"is_preprint":false},{"pmid":"31124187","id":"PMC_31124187","title":"Altered immunoreactivity of ErbB4, a causative gene product for ALS19, in the spinal cord of patients with sporadic ALS.","date":"2019","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/31124187","citation_count":15,"is_preprint":false},{"pmid":"24553453","id":"PMC_24553453","title":"Desensitization by different strategies of epidermal growth factor receptor and ErbB4.","date":"2014","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24553453","citation_count":15,"is_preprint":false},{"pmid":"11926320","id":"PMC_11926320","title":"ErbB-4: a receptor tyrosine kinase.","date":"2002","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/11926320","citation_count":15,"is_preprint":false},{"pmid":"39794341","id":"PMC_39794341","title":"Small-molecule-induced ERBB4 activation to treat heart failure.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39794341","citation_count":14,"is_preprint":false},{"pmid":"17681096","id":"PMC_17681096","title":"ErbB4 expression and mutation in Japanese patients with lung cancer.","date":"2007","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17681096","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51148,"output_tokens":9768,"usd":0.149982,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20012,"output_tokens":4536,"usd":0.10673,"stage2_stop_reason":"end_turn"},"total_usd":0.256712,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Heregulin (neuregulin) is a specific ligand for HER4/ErbB4 that directly activates HER4's intrinsic tyrosine kinase activity and induces tyrosine phosphorylation; heregulin fails to phosphorylate HER2 in the absence of HER4, indicating HER4 is required for heregulin signal transduction.\",\n      \"method\": \"Ligand binding assays and receptor phosphorylation studies using recombinant heregulin on cell lines expressing recombinant receptors\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct biochemical assay with recombinant ligand and receptor, replicated across multiple cell lines, foundational paper\",\n      \"pmids\": [\"7902537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ErbB4 is an essential in vivo receptor for neuregulins in cardiac muscle differentiation (myocardial trabeculation) and axon guidance in the CNS hindbrain; ErbB4-null mice die mid-embryogenesis from failed ventricular trabeculation.\",\n      \"method\": \"ErbB4 knockout mice (gene targeting), histological and developmental phenotype analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with specific developmental phenotypes, replicated across multiple developmental contexts, foundational in vivo study\",\n      \"pmids\": [\"7477376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Heregulin-induced HER4 activation leads to tyrosine phosphorylation of Shc adaptor proteins, implicating Shc as a downstream signaling molecule in HER4-mediated signal transduction.\",\n      \"method\": \"Heregulin-Fc fusion protein stimulation of HER4-expressing cells, immunoprecipitation and anti-phosphotyrosine Western blot of Shc\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical identification of downstream signaling partner, single lab, two orthogonal methods (binding + phosphorylation)\",\n      \"pmids\": [\"7759543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ErbB4 homodimerization at high expression levels is required for neuregulin-stimulated, IL-3-independent cell proliferation; low ErbB4 expression allows neuregulin-induced phosphorylation but is insufficient to couple activated ErbB4 to mitogenic cellular signaling.\",\n      \"method\": \"Hammerhead ribozyme-mediated ErbB4 knockdown in 32D/ErbB4 cells, proliferation assays, receptor phosphorylation analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ribozyme KD with quantitative expression and signaling analysis, single lab with multiple readouts\",\n      \"pmids\": [\"9699674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TACE (tumor necrosis factor-alpha-converting enzyme/ADAM17) is the metalloprotease required for regulated ectodomain shedding of the HER4 JM-a isoform; the juxtamembrane sequence specific to JM-a confers susceptibility to TACE-mediated cleavage, while JM-b is resistant.\",\n      \"method\": \"TACE-deficient cells with TACE re-expression, phorbol ester and pervanadate stimulation, JM-a/JM-b isoform swap experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic loss-of-function (TACE-null cells) plus re-expression rescue, isoform domain-swap experiments, multiple stimuli tested\",\n      \"pmids\": [\"10744726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The two cytoplasmic ErbB4 isoforms (CYT-1 and CYT-2) differ in signaling: both couple to the Shc-MAPK pathway, but only CYT-1 activates PI3K-Akt signaling; CYT-2 isoform is defective in stimulating cellular survival and chemotaxis, while both can stimulate proliferation.\",\n      \"method\": \"Isoform expression in cells, signaling pathway analysis (PI3K, Akt, MAPK), functional assays (survival, chemotaxis, proliferation)\",\n      \"journal\": \"Trends in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform comparison with multiple functional readouts, single lab, review article summarizing original data\",\n      \"pmids\": [\"11343971\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Presenilin-dependent gamma-secretase processing of ErbB4 is required to release the 4ICD intracellular domain; the gamma-secretase-resistant transmembrane mutant ERBB4-V673I retains normal cell-surface signaling but fails to translocate to the nucleus, cannot activate STAT5A-driven beta-casein promoter, and fails to accumulate in mitochondria or induce apoptosis.\",\n      \"method\": \"Site-directed mutagenesis (V673I), gamma-secretase inhibitors, nuclear fractionation, STAT5A transcriptional reporter assay, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis, multiple orthogonal functional readouts (nuclear localization, transcription, apoptosis), clear mechanistic dissection\",\n      \"pmids\": [\"15746097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERBB4 potentiates STAT5A transcriptional activity through phosphorylation of STAT5A at Ser-127/Ser-128 (required for subsequent Tyr-694 phosphorylation and DNA binding) and Ser-779 (required for stable interaction with ERBB4 and gene activation); ERBB4 expression is required in vivo for STAT5A Ser-779 phosphorylation in mammary gland.\",\n      \"method\": \"Mass spectrometry identification of phosphorylation sites, serine-to-alanine mutagenesis of STAT5A, co-IP, mammary gland immunohistochemistry from ERBB4-null mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — MS site identification combined with mutagenesis, in vitro plus in vivo validation in ERBB4-null tissue, multiple orthogonal methods\",\n      \"pmids\": [\"15863494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ligand-activated ERBB4 undergoes proteolytic processing to release 4ICD, which accumulates in mitochondria and promotes cytochrome c efflux; 4ICD functions as a BH3-only protein requiring an intact BH3 domain and BAK (not BAX) to initiate mitochondrial apoptosis; BCL-2 interaction suppresses 4ICD-induced apoptosis.\",\n      \"method\": \"Ligand stimulation, subcellular fractionation, BH3 domain mutagenesis, BCL-2 overexpression, BAK/BAX siRNA knockdown, cytochrome c release assay, xenograft model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including mutagenesis, fractionation, genetic knockdown, and in vivo validation in a single study\",\n      \"pmids\": [\"16778220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Estrogen promotes association between estrogen receptor alpha (ERα) and ERBB4; the proteolytically processed 4ICD translocates to the nucleus in a ligand-bound ER-dependent manner and the nuclear ER/4ICD complex selectively coactivates estrogen-inducible promoters (PgR, SDF-1 but not pS2); ERBB4 is itself an estrogen-inducible gene, establishing an autocrine loop.\",\n      \"method\": \"Co-immunoprecipitation, nuclear translocation assay, chromatin immunoprecipitation, siRNA knockdown, transcriptional reporter assays, cell proliferation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reciprocal Co-IP, ChIP, siRNA KD with multiple transcriptional readouts, all in single lab with orthogonal methods\",\n      \"pmids\": [\"16912174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"An activating transmembrane mutation (I658E) in ERBB4 increases receptor tyrosine phosphorylation ~5-fold, enhances nuclear translocation and STAT5A-driven beta-casein promoter activation, and potentiates proapoptotic function in multiple cancer cell lines while untransformed cells are resistant.\",\n      \"method\": \"Site-directed mutagenesis, tyrosine phosphorylation assay, nuclear fractionation, STAT5A transcriptional reporter, apoptosis assays across multiple cell lines\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis with multiple functional readouts, single lab\",\n      \"pmids\": [\"16832345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Heregulin/HER4-induced growth inhibition and G2/M delay in breast cancer cells requires BRCA1 induction via JNK signaling; HER4 activates JNK to upregulate BRCA1 expression independent of HER2 and cell cycle phase; BRCA1 knockdown abolishes HER4-mediated mitotic delay.\",\n      \"method\": \"Heregulin stimulation, pharmacological JNK/ERK inhibition, siRNA BRCA1 knockdown, isogenic BRCA1+/- mouse mammary epithelial cells, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (isogenic BRCA1 +/-), siRNA KD, pharmacological inhibition all converging on same mechanism, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"16914727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The CYT-2 ErbB4 ICD (ICD2) accumulates in the nucleus to a significantly greater extent than CYT-1 ICD (ICD1); ICD2 shows higher tyrosine phosphorylation and greater in vitro kinase activity than ICD1; kinase-dead ICD2 K751R mutation blocks tyrosine phosphorylation and significantly reduces nuclear translocation; ICD2 is more efficient than ICD1 in promoting STAT5 target gene beta-casein transcription.\",\n      \"method\": \"Confocal microscopy, nuclear fractionation, in vitro kinase assay, site-directed mutagenesis (K751R), STAT5 transcriptional reporter\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (imaging, fractionation, in vitro kinase, mutagenesis, transcription), mechanistic dissection of isoform-specific nuclear localization\",\n      \"pmids\": [\"17486069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ErbB4, as a postsynaptic target of NRG1, is recruited into excitatory synapses by synaptic activity; overexpressed ErbB4 selectively enhances AMPA synaptic currents and increases dendritic spine size; preventing NRG1/ErbB4 signaling destabilizes synaptic AMPA receptors and causes loss of synaptic NMDA currents and spines.\",\n      \"method\": \"Electrophysiology (patch clamp), ErbB4 overexpression and dominant negative, live imaging, spine morphology analysis in hippocampal neurons\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct electrophysiological measurements combined with structural (spine) readouts, gain- and loss-of-function approaches, multiple orthogonal methods\",\n      \"pmids\": [\"17521571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms reveal that active ErbB4 kinase adopts an asymmetric dimer conformation identical to that of activated EGFR/ErbB1; mutagenesis of intact ErbB4 in Ba/F3 cells confirms the functional importance of this asymmetric dimer for ErbB4 activation; lapatinib binds an inactive kinase conformation.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, functional kinase activity assays in Ba/F3 cells\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis validation in cells, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"18334220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"4ICD functions as an ERα coactivator and, upon tamoxifen treatment, the ERα-4ICD interaction is disrupted while 4ICD accumulates in mitochondria as a proapoptotic BH3-only protein; BAK activation (independent of BAX) and BCL-2 inhibition of tamoxifen apoptosis support 4ICD involvement; HER4 with mutated BH3 domain fails to restore tamoxifen sensitivity in xenograft model.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, tamoxifen resistance models, BH3 domain mutagenesis, xenograft experiments, apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis, multiple cell models, in vivo xenograft with domain-specific mutant, mechanistic dissection across multiple orthogonal methods\",\n      \"pmids\": [\"18676864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Her4 kinase domain is activated ~40-fold upon nickel-liposome-mediated dimerization in a concentration-dependent, sigmoidal (cooperative) manner consistent with asymmetric dimer activation; Her3 activates Her2/neu but is a poor activator of Her4; mutation of Her3 C-lobe residues (952)ENI(954) to Her4-corresponding sequence enhances Her3-mediated Her4 activation, demonstrating sequence-specific heterodimerization requirements.\",\n      \"method\": \"Reconstituted in vitro kinase assay with nickel-chelating lipid-liposomes, autophosphorylation assay, site-directed mutagenesis of Her3\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, direct mechanistic demonstration of asymmetric dimer activation and sequence determinants\",\n      \"pmids\": [\"20022944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ErbB4 JM-a isoform promotes enhanced autophosphorylation and cell survival via release of soluble ICD that associates with transcription factor AP-2 to promote PDGFRA transcription; JM-b isoform cells undergo starvation-induced death; PDGFR-α and AP-2 are required for JM-a survival; cells expressing JM-b are rescued by PDGF-BB, identifying PDGFRA as an ErbB4 isoform-specific target gene.\",\n      \"method\": \"ErbB4 isoform expression in fibroblasts, PDGFRA expression analysis, AP-2 co-immunoprecipitation, pharmacological PDGFR-α targeting, rescue experiments with PDGF-BB\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform comparison with mechanistic follow-up (Co-IP, pharmacological and genetic inhibition), single lab\",\n      \"pmids\": [\"20943952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"KRAB-associated protein 1 (Kap1) binds to multiple ErbB4 isoforms independently of ErbB4 kinase activity and is not an ErbB4 substrate; Kap1 reduces ERBB4 transcription; ErbB4 upregulation and MDM2 suppression jointly accelerate p21(CIP1) accumulation in response to DNA damage.\",\n      \"method\": \"Proteomic screen for ErbB4 ICD interactors, Co-IP, transcriptional analysis, DNA damage response assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — proteomic screen plus Co-IP validation, functional follow-up with DNA damage, single lab\",\n      \"pmids\": [\"20858735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ErbB4 promotes COX-2 expression in colon epithelial cells by increasing COX-2 mRNA stability through a Src- and PI3K-dependent mechanism; ErbB4 transactivates EGFR upon heregulin stimulation via heterodimerization, and COX-2 inhibition reverses ErbB4-mediated cell survival and soft-agar colony formation.\",\n      \"method\": \"ErbB4 overexpression and siRNA knockdown, mRNA stability assay, pharmacological inhibition of Src/PI3K/COX-2, EGFR phosphorylation assay, anchorage-independent growth assay\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling pathway inhibitors plus siRNA KD with mechanistic readouts, single lab\",\n      \"pmids\": [\"20585313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ErbB4 associates with GABAA receptor α1 subunit (GABAR α1) in hippocampal interneurons; a NRG1-mediated ErbB4 signaling pathway, independent of its tyrosine kinase activity, reduces postsynaptic GABAA receptor currents on inhibitory interneurons via clathrin-mediated endocytosis and protein kinase C; ErbB4-null mice have diminished cortical GABAR α1 expression.\",\n      \"method\": \"Unbiased proteomics, electrophysiology, Co-immunoprecipitation, pharmacological inhibition of endocytosis/PKC, immunohistochemistry, ErbB4-null mice\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — proteomic identification, Co-IP, electrophysiology, pharmacological dissection, and genetic KO all converging on same mechanism in single study\",\n      \"pmids\": [\"24218551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ALS19-associated ERBB4 mutations (p.Arg927Gln in kinase domain; p.Arg1275Trp in C-terminal domain) reduce autophosphorylation of ErbB4 upon NRG-1 stimulation, establishing that loss of neuregulin-ErbB4 signaling underlies ALS pathogenesis.\",\n      \"method\": \"Functional analysis of ERBB4 mutants: ErbB4 autophosphorylation assay upon NRG-1 stimulation, comparison of wild-type vs. mutant receptor activity\",\n      \"journal\": \"American Journal of Human Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay of patient-derived mutants, single lab, limited to autophosphorylation readout\",\n      \"pmids\": [\"24119685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERBB4 activates the SREBP-2 cholesterol biosynthetic pathway via PI3K and mTORC1/2 (but not AKT or mTORC1 alone) signaling downstream; NRG1-activated ERBB4 ICD induces SREBP-2 target genes (HMGCR, HMGCS1, LDLR) to increase LDL uptake and cholesterol biosynthesis; SREBP site 1 protease inhibition or pan-ERBB inhibition (lapatinib) blocks NRG1-induced cholesterol gene expression.\",\n      \"method\": \"ERBB4 ICD expression in mammary epithelial cells, NRG1 stimulation, pharmacological inhibitors of PI3K/mTOR/AKT/lapatinib/erlotinib, gene expression analysis, LDL uptake assay\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors and gene expression validation, single lab\",\n      \"pmids\": [\"26535009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Four activating ERBB4 mutations in lung adenocarcinoma (Y285C, D595V, D931Y, K935I) increase basal and ligand-induced ErbB4 phosphorylation, enhance ErbB4 dimerization and trans-activation in both homodimers and ErbB4-ErbB2 heterodimers, and markedly increase proteolytic release of signaling-competent ErbB4 ICD.\",\n      \"method\": \"Mutant ERBB4 expression in NIH 3T3 cells, phosphorylation assays, dimerization assays, structural analysis, ICD release measurement\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional characterization of multiple mutants with mechanistic assays (dimerization, phosphorylation, ICD release), single lab\",\n      \"pmids\": [\"26050618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ErbB4 in pro-inflammatory macrophages localizes to mitochondria; NRG4-induced ErbB4 activation causes mitochondrial membrane potential loss and apoptosis requiring proteases that generate the cleaved ErbB4 ICD, consistent with mitochondrial pathway apoptosis; NRG4/ErbB4 signaling limits colitis by clearing pro-inflammatory macrophages.\",\n      \"method\": \"Immunofluorescence (ErbB4 mitochondrial localization), NRG4 treatment, pharmacological protease inhibition, mitochondrial membrane potential assay, apoptosis assays in murine and human macrophages, DSS colitis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment tied to functional consequence, pharmacological dissection, in vivo colitis model, single lab\",\n      \"pmids\": [\"28230865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ErbB4 deletion in the liver suppresses p53 expression by inhibiting TP53INP1 expression, establishing an ERBB4-TP53INP1-P53 axis in hepatocellular carcinoma suppression.\",\n      \"method\": \"Liver-specific ErbB4 knockout mice, DEN-induced tumor model, microarray gene expression analysis, real-time PCR validation\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with mechanistic pathway identification via transcriptomics plus validation, single lab\",\n      \"pmids\": [\"28334319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ErbB4 promotes inhibitory synapse formation through kinase-independent trans-adhesion: ErbB4 interacts in trans with postsynaptic Slitrk3 via ErbB4's extracellular RLD domain; kinase-dead ErbB4 K751M knock-in mice have normal inhibitory synapse numbers (unlike ErbB4-null mice), confirming kinase-independent mechanism.\",\n      \"method\": \"HEK293T co-culture synapse formation assay, K751M kinase-dead mutant KI mice, ErbB4 RLD domain deletion, Slitrk3 neutralization, GABAergic transmission electrophysiology, immunostaining\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis (kinase dead), KI mice, domain deletion, neutralization experiments, electrophysiology—multiple orthogonal methods establishing kinase-independent adhesion mechanism\",\n      \"pmids\": [\"34226493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"S100A4 neuroprotection depends on ErbB4 expression and ErbB2/Akt signaling downstream of ErbB4; S100A4 and S100A4-derived peptides interact with ErbB4 (as well as ErbB1 and ErbB3) and signal through ErbB receptors to promote neuronal survival.\",\n      \"method\": \"ErbB4 expression-dependent neuroprotection assays, functional ErbB4 blockade, ErbB2/Akt inhibition, binding assays\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, binding and functional assays without full mechanistic resolution of direct vs. indirect S100A4-ErbB4 interaction\",\n      \"pmids\": [\"30083275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Acute ErbB4 kinase inactivation (chemical genetics) and optogenetic inhibition of ErbB4+ interneurons in the hippocampus reduce GABAergic activity, impair hippocampal-prefrontal synchrony, and diminish top-down attention; ErbB4 inactivation in prefrontal cortex alters attention but not synchrony, establishing hippocampal ErbB4 as specifically required for hippocampal-prefrontal synchronization.\",\n      \"method\": \"Chemical genetic ErbB4 kinase inactivation, optogenetic interneuron inhibition, in vivo LFP recording, attention behavioral assays in ErbB4 mutant mice\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — chemical genetics plus optogenetics with in vivo electrophysiology, region-specific dissection, multiple complementary approaches\",\n      \"pmids\": [\"29628188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNF transactivates ErbB4 through TACE-dependent release of HB-EGF; MEK (but not Src or p38) is required for this transactivation; TACE inhibition or ErbB4 ligand-binding blockade reverses ErbB4-mediated protection of colonic epithelial cells from TNF-induced apoptosis.\",\n      \"method\": \"Neutralizing antibodies against HB-EGF, pharmacological/genetic TACE inhibition, MEK/Src/p38 inhibitors, apoptosis assays in ErbB4-expressing mouse colon epithelial cells\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological and antibody-based pathway dissection approaches, single lab\",\n      \"pmids\": [\"21617117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In adult rat ventricular myocytes (ARVM), ErbB4 localizes to the nucleus as a full-length protein (not requiring PKC or gamma-secretase), as only the non-cleavable JM-b isoform is expressed in ARVM; ErbB4 kinase activity is required for doxorubicin-induced p53 and p21 upregulation in cardiac myocytes.\",\n      \"method\": \"Nuclear fractionation, isoform expression analysis, gamma-secretase/PKC inhibitors, ErbB4 siRNA knockdown, doxorubicin DNA damage assay, p53/p21 expression analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct fractionation with isoform analysis, pharmacological and siRNA-based functional dissection, single lab\",\n      \"pmids\": [\"22244893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PTPN21 de-phosphorylates ErbB4, leading to upregulation of ErbB4 downstream signaling; phosphatase-dead PTPN21 (C1108S) and kinase-dead ErbB4 (K751R) both impede PTPN21-dependent signaling; PTPN21 promotes NRG3 expression through Elk-1 activation downstream of ErbB4.\",\n      \"method\": \"Biotinylated receptor tracking, immunoprecipitation, PTPN21 and ErbB4 kinase-dead mutants, Elk-1 transcriptional analysis, NRG3 promoter analysis in cortical neurons\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP, domain mutants, transcriptional analysis, single lab with multiple approaches\",\n      \"pmids\": [\"25681686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ErbB4 promotes malignant peripheral nerve sheath tumor (MPNST) proliferation and survival via Ras-independent signaling through STAT3, STAT5, and phospholipase-Cγ pathways; ErbB4 ablation reduces Ras-independent kinase cascades while broad-spectrum ErbB inhibitors suppress Ras activation, demonstrating distinct ErbB4-specific signaling.\",\n      \"method\": \"Conditional Erbb4 knockout in MPNST mice, orthotopic xenografts of Erbb4-null cells, antibody kinase arrays (43 candidate kinases), pharmacological inhibition of STAT3/STAT5/PLCγ, proliferation and survival assays\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO in vivo plus in vitro kinase array with pharmacological validation, single lab\",\n      \"pmids\": [\"31291965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ErbB4 mediates Aβ-induced neurotoxicity through JNK/tau pathway activation; Aβ activates JNK via ErbB4 (distinct from NRG1β1-ErbB4 signaling), and ErbB4 siRNA knockdown decreases JNK and tau phosphorylation at Ser396/Thr205, Bax expression, and PSD-95/synaptophysin loss.\",\n      \"method\": \"ErbB4 siRNA knockdown, ErbB4 kinase inhibitor (AG1478), PV neuron-specific ErbB4 conditional KO, phosphorylation assays for JNK and tau, Western blot, hAPP-J20 mouse model\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, pharmacological inhibition, and siRNA with mechanistic pathway markers, single lab\",\n      \"pmids\": [\"34212389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of near full-length HER2/HER4 heterodimers and full-length HER4 homodimers bound to NRG1β and BTC reveal: HER2/HER4 heterodimer interface is less dynamic than HER2/EGFR or HER2/HER3; HER4 homodimers exhibit more large-scale dynamics than HER2/HER4 heterodimers; multiple glycan modifications on HER4 ectodomains stabilize HER4 homodimer interfaces over HER2/HER4 heterodimer interfaces.\",\n      \"method\": \"Cryo-EM structure determination of near full-length receptor complexes, structural dynamics analysis, glycan modeling\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures with near full-length constructs, multiple complexes compared, first glycan modeling in HER receptors\",\n      \"pmids\": [\"38498590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Small-molecule compounds (EF-1 to EF-8) can activate ERBB4 by inducing receptor dimerization; EF-1 reduces cardiomyocyte death and hypertrophy and decreases cardiac fibroblast collagen production in an ERBB4-dependent manner; in vivo, EF-1 inhibits angiotensin-II-induced fibrosis and reduces doxorubicin/MI-induced heart damage, with no effect in Erbb4-null mice.\",\n      \"method\": \"Small-molecule screen (10,240 compounds), ERBB4 dimerization assay, cardiomyocyte and fibroblast cell assays, Erbb4-null mouse model with angiotensin-II, doxorubicin, and MI models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanism validated in Erbb4-null mice (genetic negative control), multiple in vivo cardiac injury models, orthogonal cellular assays\",\n      \"pmids\": [\"39794341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Peripheral Nrg4 signals via ErbB4 in hypothalamic paraventricular nucleus (PVN) oxytocin neurons; ErbB4 overexpression in PVN protects against obesity while ErbB4 knockdown in oxytocin neurons accelerates obesity; Nrg4-ErbB4 signaling excites oxytocin release, and oxytocin neuron ablation attenuates Nrg4's effect on energy balance.\",\n      \"method\": \"PVN ErbB4 overexpression, oxytocin neuron-specific ErbB4 knockdown, central rNrg4 administration, oxytocin neuron ablation, metabolic phenotyping in DIO mice\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic manipulations with functional metabolic readouts and epistasis, single lab\",\n      \"pmids\": [\"37060105\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERBB4/HER4 is a receptor tyrosine kinase activated by neuregulins (and other EGF-family ligands) that signals through ligand-induced asymmetric kinase domain dimerization, leading to autophosphorylation and downstream activation of Shc-MAPK, PI3K-Akt (isoform-dependent), STAT5A, and PLCγ pathways; uniquely among ErbB receptors, ERBB4 undergoes sequential ectodomain shedding by TACE (isoform JM-a only) followed by presenilin/γ-secretase cleavage to release a soluble intracellular domain (4ICD) that translocates to the nucleus to coactivate STAT5A and ERα-driven transcription, or to mitochondria where it acts as a BH3-only protein to trigger BAK-dependent apoptosis; additionally, ErbB4 promotes inhibitory synapse formation through kinase-independent trans-interaction with Slitrk3 via its extracellular RLD domain, and regulates GABAergic interneuron function to control hippocampal-prefrontal synchrony and cortical circuit activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ERBB4/HER4 is a neuregulin-activated receptor tyrosine kinase that couples extracellular EGF-family ligand binding to both canonical cytoplasmic signaling and a distinctive nuclear/mitochondrial signaling mode, with essential roles in cardiac and neural development, GABAergic circuit function, and tissue homeostasis [#0, #1]. Ligand binding drives formation of an asymmetric kinase-domain dimer structurally identical to that of activated EGFR, which is required for kinase activation and autophosphorylation [#14, #16], and cryo-EM of near-full-length HER4 homodimers and HER2/HER4 heterodimers shows that glycan modifications and interface dynamics distinguish these dimer states [#34]. Activated ERBB4 engages the Shc-MAPK pathway and, in an isoform-dependent manner, PI3K-Akt: the CYT-1 cytoplasmic isoform activates PI3K-Akt and supports survival and chemotaxis whereas CYT-2 does not [#2, #5]. Uniquely among ErbB receptors, the JM-a isoform undergoes sequential TACE/ADAM17-mediated ectodomain shedding followed by presenilin/\\u03b3-secretase cleavage to release a soluble intracellular domain (4ICD); blocking \\u03b3-secretase cleavage abolishes nuclear translocation, STAT5A-driven transcription, mitochondrial accumulation, and apoptosis [#4, #6]. In the nucleus 4ICD potentiates STAT5A activity through direct serine phosphorylation events and coactivates ER\\u03b1 at estrogen-responsive promoters, forming an autocrine loop with estrogen-induced ERBB4 [#7, #9], while at mitochondria 4ICD acts as a BH3-only protein requiring an intact BH3 domain and BAK to trigger cytochrome c release and apoptosis, an activity suppressed by BCL-2 [#6, #15]. In the nervous system ErbB4 mediates NRG1 signaling to control excitatory and inhibitory synapses and GABAergic interneuron function, governing hippocampal-prefrontal synchrony and attention [#13, #28]; it also promotes inhibitory synapse formation through a kinase-independent trans-adhesive interaction with Slitrk3 via its extracellular RLD domain [#26]. Timeline evidence links ERBB4 mutations that reduce NRG1-stimulated autophosphorylation to amyotrophic lateral sclerosis (ALS19) [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that HER4/ErbB4 is a functional receptor whose intrinsic kinase is directly activated by heregulin/neuregulin, defining the ligand-receptor relationship at the heart of the pathway.\",\n      \"evidence\": \"Recombinant heregulin binding and receptor phosphorylation assays in cell lines expressing recombinant receptors\",\n      \"pmids\": [\"7902537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve downstream effectors\", \"Did not address receptor dimerization or activation mechanism\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated that ErbB4 is an essential in vivo neuregulin receptor, anchoring its developmental requirement in cardiac trabeculation and CNS axon guidance.\",\n      \"evidence\": \"ErbB4 knockout mice with histological developmental phenotyping\",\n      \"pmids\": [\"7477376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Embryonic lethality limits analysis of later/adult roles\", \"Cell-autonomous vs. systemic contributions not separated\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identified Shc as an immediate downstream adaptor, beginning the mapping of ErbB4's cytoplasmic signaling outputs.\",\n      \"evidence\": \"Heregulin-Fc stimulation with Shc immunoprecipitation and anti-phosphotyrosine blotting\",\n      \"pmids\": [\"7759543\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not connect Shc to a specific phenotype\", \"Single readout of phosphorylation\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved the protease and isoform determinants of ectodomain shedding, showing TACE/ADAM17 cleaves only the JM-a isoform — the prerequisite for regulated intracellular signaling.\",\n      \"evidence\": \"TACE-null cells with re-expression rescue and JM-a/JM-b isoform-swap experiments\",\n      \"pmids\": [\"10744726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address the second (gamma-secretase) cleavage step\", \"Physiological triggers of shedding beyond phorbol ester/pervanadate not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined functional divergence of the cytoplasmic CYT-1/CYT-2 isoforms, establishing PI3K-Akt coupling as a CYT-1-specific output for survival and chemotaxis.\",\n      \"evidence\": \"Isoform expression with PI3K/Akt/MAPK signaling and functional survival, chemotaxis, proliferation assays\",\n      \"pmids\": [\"11343971\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-summarized original data\", \"Molecular basis of differential PI3K recruitment not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed presenilin/gamma-secretase cleavage is required to liberate 4ICD, linking proteolysis to nuclear translocation, STAT5A transcription, and mitochondrial apoptosis through a single non-cleavable mutant.\",\n      \"evidence\": \"V673I cleavage-resistant mutant, gamma-secretase inhibitors, nuclear fractionation, STAT5A reporter and apoptosis assays\",\n      \"pmids\": [\"15746097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define nuclear import machinery\", \"Mitochondrial targeting determinants left open\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the molecular basis of ERBB4-STAT5A coactivation via specific serine phosphorylations required for STAT5A activation and stable interaction, validated in ERBB4-null mammary tissue.\",\n      \"evidence\": \"Mass spectrometry site mapping, STAT5A serine-to-alanine mutagenesis, co-IP, and ERBB4-null mammary immunohistochemistry\",\n      \"pmids\": [\"15863494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether full-length receptor or 4ICD performs the phosphorylation in vivo not fully resolved\", \"Genome-wide STAT5A target scope not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established 4ICD as a BH3-only proapoptotic effector, identifying BAK (not BAX) dependence and BCL-2 antagonism as the mitochondrial death mechanism.\",\n      \"evidence\": \"Subcellular fractionation, BH3 mutagenesis, BAK/BAX siRNA, cytochrome c release, BCL-2 overexpression, and xenografts\",\n      \"pmids\": [\"16778220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct 4ICD-BAK binding stoichiometry not determined\", \"Conditions favoring apoptotic vs. transcriptional 4ICD fate unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked 4ICD to estrogen signaling as an ERalpha coactivator at selected promoters, with ERBB4 itself estrogen-inducible, establishing an autocrine transcriptional loop.\",\n      \"evidence\": \"Reciprocal co-IP, ChIP, siRNA knockdown, and transcriptional reporter assays\",\n      \"pmids\": [\"16912174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Basis of promoter selectivity (PgR/SDF-1 vs pS2) not explained\", \"Interplay with STAT5A coactivation not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected ErbB4 to a tumor-suppressive cell-cycle arrest via JNK-driven BRCA1 induction, showing growth-inhibitory as well as proliferative outputs.\",\n      \"evidence\": \"Heregulin stimulation, JNK/ERK inhibition, BRCA1 siRNA, isogenic BRCA1+/- cells, and cell cycle analysis\",\n      \"pmids\": [\"16914727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How JNK is selectively engaged by ErbB4 not defined\", \"Reconciliation with proliferative signaling context-dependent\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Provided the structural basis of ErbB4 kinase activation, showing the active kinase forms an asymmetric dimer identical to EGFR and that lapatinib traps an inactive conformation.\",\n      \"evidence\": \"X-ray crystallography of active and lapatinib-bound kinase domains plus mutagenesis in Ba/F3 cells\",\n      \"pmids\": [\"18334220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length ectodomain-mediated dimerization not captured\", \"Heterodimer-specific activation not addressed structurally\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Quantified cooperative asymmetric-dimer activation in vitro and defined C-lobe sequence determinants governing which partner activates Her4, explaining heterodimer selectivity.\",\n      \"evidence\": \"Reconstituted nickel-liposome kinase assays with Her3 C-lobe mutagenesis\",\n      \"pmids\": [\"20022944\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro liposome system may not capture full-length cellular regulation\", \"Physiological partner hierarchy in cells not ranked\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Multiple isoform-, mutation-, and context-specific signaling outputs (CYT-1/CYT-2 nuclear potency, PDGFRA/AP-2 and SREBP-2 transcriptional programs, KAP1/PTPN21 regulation, cancer-activating mutations, neuronal NRG/ErbB4 circuit and disease links in ALS and Alzheimer's, and cardioprotective small-molecule agonism) extend the model but the rules that select between cytoplasmic, nuclear-transcriptional, and mitochondrial-apoptotic ErbB4 fates in a given cell remain unresolved.\",\n      \"evidence\": \"Spanning isoform, proteomic, mutational, metabolic, neuronal, and pharmacological studies across the timeline\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying determinant of 4ICD trafficking fate\", \"Direct S100A4-ErbB4 interaction not resolved (Low-confidence)\", \"Disease mechanisms beyond receptor-level readouts incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 7, 14, 16]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 13]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [7, 9, 17]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [26]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [6, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 14]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 9, 12, 30]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [6, 15, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 5, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 15, 24]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 9, 17]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [13, 20, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NRG1\", \"SHC1\", \"STAT5A\", \"ESR1\", \"BAK1\", \"BCL2\", \"SLITRK3\", \"PTPN21\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}